Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type ...

Gastric cancer remains a leading cause of cancer mortality worldwide, with peritoneal dissemination accounting for a substantial proportion of recurrences and treatment failures. Cytoreductive surgery ...

HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...

Heating chemotherapy and administering it into the abdominal cavity allows children with desmoplastic small round cell tumors to be treated with minimal side effects. Hyperthermic intraperitoneal ...

CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...

Hyperthermic intraperitoneal chemotherapy (HIPEC) provides an important treatment option that can improve survival for some patients with advanced peritoneal cancer. Managing this disease — and ...

Ten-year relative suvival for ovarian cancer. Background: When GOG 172 showed a benefit to intraperitoneal (IP) chemotherapy as frontline treatment for advanced ovarian cancer, our division adopted IP ...

CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...

WEST PHILADELPHIA (WPVI) -- Chemotherapy is a lifesaver in cancer treatment. But an IV isn't always the best way to deliver it. A different technique is helping make a difference for some abdominal ...

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

Response outcomes compared favorably with historical single-agent pembrolizumab activity in recurrent ovarian cancer (KEYNOTE ...